Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Medicine (Baltimore). 2023 Jul 28;102(30):e34356. doi: 10.1097/MD.0000000000034356.
To determine the effect of prolotherapy on functional outcome changes, along with ratio of matrix metalloproteinase-1 (MMP-1)/tissue inhibitor matrix metalloproteinase-1 (TIMP-1) as an indicator of tissue repair in the glenohumeral joint in frozen shoulder patients.
Single-blinded randomized controlled trial.
SUBJECTS/PATIENTS: Participants with frozen shoulder.
The prolotherapy group is the study group, and the normal saline (NS) group is the control group. Each group was given injections at weeks 0, 2, 4, and 6. Level of biomarker levels was measured at week 6 and week 12 after there. Functional outcomes were measured at weeks 0, 6, and 12.
A significant difference in week 6 and week 12 was demonstrated in the ratio of MMP-1/TIMP-1 level between the prolotherapy group and the normal saline group (P value = .002). Both groups performed well regarding the Numerical Rating Scale score and functional outcome. Compared to the normal saline group, prolotherapy changed the mean range of motion in flexion and internal rotation.
Prolotherapy is considered to play a role in repairing cartilage based on biomarker assessment, particularly the ratio of MMP-1/TIMP-1-prolotherapy effectiveness in improving functional outcome and Numerical Rating Scale score.
确定增生疗法对功能结果变化的影响，以及基质金属蛋白酶-1（MMP-1）/组织抑制剂基质金属蛋白酶-1（TIMP-1）的比率作为肩峰下关节中冷冻肩患者组织修复的指标。
单盲随机对照试验。
受试者/患者：患有冻结肩的参与者。
增生疗法组为研究组，生理盐水（NS）组为对照组。每组在 0 周、2 周、4 周和 6 周时给予注射。在第 6 周和第 12 周后测量生物标志物水平。在第 0 周、第 6 周和第 12 周测量功能结果。
在第 6 周和第 12 周，增生疗法组和生理盐水组之间 MMP-1/TIMP-1 水平的比率存在显著差异（P 值=0.002）。两组在数字评分量表评分和功能结果方面均表现良好。与生理盐水组相比，增生疗法改变了屈曲和内旋的平均活动范围。
基于生物标志物评估，增生疗法被认为在修复软骨方面发挥作用，特别是 MMP-1/TIMP-1 的比率-增生疗法在改善功能结果和数字评分量表评分方面的有效性。
